Clinical Trials on Neoplasms, Plasma Cell

Total 110035 results

IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation

Completed

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Primary Plasma Cell Leukemia

Italy
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm | Malignant Plasma Cell Neoplasm

United States
Masonic Cancer Center, University of Minnesota

Terminated

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Germ Cell Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore

Completed

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Masonic Cancer Center, University of Minnesota

Terminated

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Puerto Rico, South Africa
Sparrow Regional Cancer Center

Unknown

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Multiple Myeloma and Plasma Cell Neoplasm

United States
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Medsearch

Unknown

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic

Completed

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Immune Control

Completed

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Netherlands, Belgium
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
West of Scotland Lymphoma Group

Completed

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Roswell Park Cancer Institute

Terminated

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Multiple Myeloma and Plasma Cell Neoplasm
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Poniard Pharmaceuticals

Completed

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Unknown

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Completed

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma

United States
NCIC Clinical Trials Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); European Organisation for Research and Treatment... and other collaborators

Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Canada
Roswell Park Cancer Institute

Completed

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
NCIC Clinical Trials Group

Completed

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Study of DNA Samples From Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide

Multiple Myeloma and Plasma Cell Neoplasm

Clinical Trials on Neoplasms, Plasma Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations